secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001437749-23-027662
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen raises $100M via underwritten offering with warrants; proceeds fund fasedienol Phase 3
--------------------------------------------------------------------------------

- Gross proceeds ~$100M; net proceeds ~$93.5M after underwriting discounts and expenses.
- Offering includes 15.0M shares of common stock and up to 20.6M warrants (T1: $5.38 strike, T2: $8.877 strike).
- Led by BVF Partners with participation from Commodore Capital, Great Point Partners, Logos Capital, Nantahala Capital, Surveyor Capital, and TCGX.
- Proceeds to fund PALISADE Phase 3 for fasedienol in social anxiety disorder; expected to support operations through potential NDA submission.
- Offering closed October 4, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923027662/0001437749-23-027662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923027662/vtgn20231003_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-027662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer